AAP
ACRS icon

Arax Advisory Partners’s Aclaris Therapeutics ACRS Stock Holding History

Arax Advisory Partners’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-19
Closed -$57 – 3772
2025
Q4 		$57 Sell
19
-428
-96% -$1.08K ﹤0.01% 3901
2025
Q3 		$849 Buy
+447
New +$779 ﹤0.01% 3294
2024
Q4 		– Sell
-1,632
Closed -$1.88K – 2417
2024
Q3 		$1.88K Hold
1,632
– – ﹤0.01% 2087
2024
Q2 		$1.8K Buy
+1,632
New +$1.92K ﹤0.01% 2003

Other funds holding ACRS

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Arax Advisory Partners's ACRS Position: Q1 2026 in Review

Arax Advisory Partners sold out of Aclaris Therapeutics (ACRS) in Q1 2026, closing a stake of 19 shares — an estimated $57 sold.

Arax Advisory Partners first reported a position in ACRS in Q2 2024 and held it in 4 quarters. The position peaked at $1.88K in Q3 2024. 136 funds tracked by Wall St. Rank hold ACRS as of Q1 2026.

  • Arax Advisory Partners reported no remaining Aclaris Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Arax Advisory Partners sold 19 Aclaris Therapeutics shares in Q1 2026, an estimated $57.
  • Arax Advisory Partners first reported a position in Aclaris Therapeutics in Q2 2024 and held it in 4 quarters.
  • Arax Advisory Partners's Aclaris Therapeutics position peaked at $1.88K in Q3 2024.
  • 136 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q1 2026.

Based on Arax Advisory Partners's 13F filing for Q1 2026, filed 13 May 2026.